What’s Propelling Valeant Pharmaceuticals Intl Inc to Increase So Much?

 What's Propelling Valeant Pharmaceuticals Intl Inc to Increase So Much?

The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) is a huge mover today! About 914,231 shares traded hands or 3.93% up from the average. Valeant Pharmaceuticals Intl Inc (TSE:VRX) has declined 37.12% since March 28, 2016 and is downtrending. It has underperformed by 40.13% the S&P500.
The move comes after 8 months positive chart setup for the $7.52B company. It was reported on Nov, 1 by Barchart.com. We have $35.82 PT which if reached, will make TSE:VRX worth $3.23 billion more.

Valeant Pharmaceuticals Intl Inc (TSE:VRX) Ratings Coverage

Out of 2 analysts covering Valeant Pharmaceuticals International (TSE:VRX), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. $74 is the highest target while $38 is the lowest. The $42.50 average target is 69.66% above today’s ($25.05) stock price. Valeant Pharmaceuticals International has been the topic of 14 analyst reports since October 20, 2015 according to StockzIntelligence Inc. The rating was maintained by RBC Capital Markets with “Sector Perform” on Monday, June 27. The stock has “Sector Perform” rating given by RBC Capital Markets on Monday, October 31. As per Tuesday, September 20, the company rating was maintained by RBC Capital Markets. The rating was maintained by RBC Capital Markets with “Sector Perform” on Tuesday, May 24. The firm has “Hold” rating by TD Securities given on Wednesday, July 20. The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) has “Sector Perform” rating given on Tuesday, October 11 by RBC Capital Markets. The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) earned “Buy” rating by TD Securities on Thursday, August 11. The company was maintained on Tuesday, October 25 by RBC Capital Markets. The stock has “Sector Perform” rating given by RBC Capital Markets on Monday, June 20. The firm has “Sector Perform” rating by RBC Capital Markets given on Friday, June 3.

More notable recent Valeant Pharmaceuticals Intl Inc (TSE:VRX) news were published by: Fool.com which released: “Valeant Pharmaceuticals Intl. Inc. Tumbled 12% on Monday Following Reports of …” on November 01, 2016, also Investorplace.com with their article: “Make Valeant Pharmaceuticals Intl Inc (VRX) Stock Pay YOU” published on October 28, 2016, Profitconfidential.com published: “Valeant Pharmaceuticals Intl Inc: The Price VRX Stock Bulls Require” on October 18, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (TSE:VRX) were released by: Forbes.com and their article: “Valeant Pharmaceuticals International is Now Oversold (VRX)” published on October 28, 2016 as well as Fool.com‘s news article titled: “These 2 Factors Pushed Valeant Pharmaceuticals Intl. Inc. Down 15% in September” with publication date: October 07, 2016.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $7.52 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.

VRX.TO Company Profile

Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment